Japanese PMDA approved planned Phase I study which will be locally run by Nagoya University. Press Release Presseaussendung Press Release (Japanese)

The prestigious ASCO Annual Meeting is the largest clinical oncology conference worldwide. Two contributions informed about key results with the neuroblastoma antibody APN311. One presentation introduced the novel “checkpoint blockade” cancer immunotherapy approach APN401. ASCO 2104 Poster Lametschwandtner et al ASCO 2014 Poster Ladenstein et al ASCO 2014 Poster Lode et al

Apeiron today announced the signing of two transactions as part of the worldwide commercialization of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma. Press release

Apeiron today announced that it has retained the services of Idis Ltd to initiate a Managed Access Program for its product APN311 (ch14.18/CHO), for patients with high-risk neuroblastoma. The program will run in specified countries throughout the world and is expected to be initiated in Q4 2013. Press release

APEIRON Biologics AG today announced that the clinical trial with their liposomal formulation of recombinant superoxide dismutase (project APN201) which started in March 2012 concluded with positive outcomes in all endpoints analyzed. Press release

Funds are dedicated to support further development of a compound interfering with Cbl-b as a potential immune booster and cancer drug.

Apeiron today announced the closing of a transaction with Paladin Labs Inc. (Canada) in its ongoing initiative to out-license APN311, an antibody-based immunotherapy in development for the treatment of children with high-risk neuroblastoma. Press release Presseaussendung  

APEIRON Biologics AG today announced the launch of Attoquant Diagnostics GmbH as a subsidiary. Attoquant will globally commercialize its already successfully marketed peptide analytics service RAS-Fingerprint™ and further develop the underlying platform technology. Press release Presseaussendung